Wall Street brokerages predict that Assembly Biosciences Inc (NASDAQ:ASMB) will report ($1.07) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Assembly Biosciences’ earnings. The highest EPS estimate is ($0.96) and the lowest is ($1.15). Assembly Biosciences reported earnings per share of ($0.80) during the same quarter last year, which suggests a negative year-over-year growth rate of 33.8%. The business is expected to issue its next quarterly earnings results on Monday, May 6th.
On average, analysts expect that Assembly Biosciences will report full year earnings of ($4.37) per share for the current fiscal year, with EPS estimates ranging from ($5.19) to ($3.74). For the next year, analysts anticipate that the company will report earnings of ($5.33) per share, with EPS estimates ranging from ($5.80) to ($4.85). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that follow Assembly Biosciences.
Assembly Biosciences (NASDAQ:ASMB) last posted its earnings results on Thursday, February 28th. The biopharmaceutical company reported ($1.03) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.91) by ($0.12). Assembly Biosciences had a negative net margin of 613.02% and a negative return on equity of 57.48%. The business had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $3.69 million.
NASDAQ:ASMB traded down $0.28 on Friday, reaching $15.19. The company’s stock had a trading volume of 607,901 shares, compared to its average volume of 311,168. Assembly Biosciences has a 12-month low of $13.13 and a 12-month high of $48.91. The company has a market capitalization of $388.10 million, a P/E ratio of -3.82 and a beta of 1.60.
Hedge funds have recently bought and sold shares of the stock. Tibra Equities Europe Ltd purchased a new stake in shares of Assembly Biosciences in the 1st quarter valued at $918,000. Man Group plc raised its holdings in shares of Assembly Biosciences by 19.6% in the 3rd quarter. Man Group plc now owns 36,042 shares of the biopharmaceutical company’s stock valued at $1,338,000 after buying an additional 5,904 shares during the period. Marshall Wace LLP purchased a new stake in shares of Assembly Biosciences in the 3rd quarter valued at $11,224,000. Victory Capital Management Inc. raised its holdings in shares of Assembly Biosciences by 3.4% in the 4th quarter. Victory Capital Management Inc. now owns 530,909 shares of the biopharmaceutical company’s stock valued at $12,009,000 after buying an additional 17,669 shares during the period. Finally, Vanguard Group Inc raised its holdings in shares of Assembly Biosciences by 29.4% in the 3rd quarter. Vanguard Group Inc now owns 1,051,454 shares of the biopharmaceutical company’s stock valued at $39,052,000 after buying an additional 238,952 shares during the period. Hedge funds and other institutional investors own 83.77% of the company’s stock.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.
Further Reading: Stochastic Momentum Index (SMI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.